HNSCC-话题@MedSci

#HNSCC#

8篇内容 | 1176人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2219445, encodeId=4ed8221944545, content=<a href='/topic/show?id=4b88612e5e' target=_blank style='color:#2F92EE;'>#DNA甲基化#</a> <a href='/topic/show?id=f28e900536' target=_blank style='color:#2F92EE;'>#HNSCC#</a> <a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, objectTitle=Cancer Res：南京医科大学程杰/王琰玲合作探索不同头颈部鳞状细胞癌亚型的生物特征和治疗易感性, objectType=article, longId=838446, objectId=343c8384461c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240806/1722940860678_8538692.png, objectUrl=/article/show_article.do?id=343c8384461c, replyNumber=0, likeNumber=62, createdTime=2024-08-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=343c8384461c, moduleTitle=Cancer Res：南京医科大学程杰/王琰玲合作探索不同头颈部鳞状细胞癌亚型的生物特征和治疗易感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=343c8384461c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1629139, encodeId=c71e1629139fd, content=<a href='/topic/show?id=f28e900536' target=_blank style='color:#2F92EE;'>#HNSCC#</a>, objectTitle=Front Oncol：复发或转移性头颈部鳞癌(R/M HNSCC)患者使用免疫检查点抑制剂治疗(ICB)的疗效, objectType=article, longId=295059, objectId=afe5295059f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afe5295059f2, replyNumber=0, likeNumber=92, createdTime=2022-02-04, rootId=0, userName=huirong, userId=27ec21318163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afe5295059f2, moduleTitle=Front Oncol：复发或转移性头颈部鳞癌(R/M HNSCC)患者使用免疫检查点抑制剂治疗(ICB)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afe5295059f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1629138, encodeId=1aee16291382b, content=<a href='/topic/show?id=f28e900536' target=_blank style='color:#2F92EE;'>#HNSCC#</a>, objectTitle=J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究, objectType=article, longId=294454, objectId=3f302944546a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f302944546a, replyNumber=0, likeNumber=56, createdTime=2022-01-23, rootId=0, userName=huirong, userId=27ec21318163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f302944546a, moduleTitle=J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f302944546a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1629137, encodeId=e078162913e38, content=<a href='/topic/show?id=f28e900536' target=_blank style='color:#2F92EE;'>#HNSCC#</a>, objectTitle=Front Oncol：每周PCC方案（紫杉醇+卡铂+西妥昔单抗）可用于不适合EXTREME方案治疗复发和/或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者, objectType=article, longId=219629, objectId=09d321962921, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09d321962921, replyNumber=0, likeNumber=51, createdTime=2021-11-03, rootId=0, userName=huirong, userId=27ec21318163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09d321962921, moduleTitle=Front Oncol：每周PCC方案（紫杉醇+卡铂+西妥昔单抗）可用于不适合EXTREME方案治疗复发和/或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09d321962921)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1629136, encodeId=a6511629136ec, content=<a href='/topic/show?id=f28e900536' target=_blank style='color:#2F92EE;'>#HNSCC#</a>, objectTitle=JNCCN：头颈部鳞状细胞癌(HNSCC)患者术后放疗（PORT）延迟会导致复发率增高并且OS降低, objectType=article, longId=217603, objectId=e41921e6037a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e41921e6037a, replyNumber=0, likeNumber=67, createdTime=2021-09-26, rootId=0, userName=huirong, userId=27ec21318163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e41921e6037a, moduleTitle=JNCCN：头颈部鳞状细胞癌(HNSCC)患者术后放疗（PORT）延迟会导致复发率增高并且OS降低, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e41921e6037a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1629135, encodeId=5d43162913589, content=<a href='/topic/show?id=f28e900536' target=_blank style='color:#2F92EE;'>#HNSCC#</a>, objectTitle=Lancet oncol：派姆单抗联合西妥昔单抗治疗复发性/转移性HNSCC的疗效和安全性, objectType=article, longId=211288, objectId=122f21128838, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=122f21128838, replyNumber=0, likeNumber=77, createdTime=2021-05-15, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=122f21128838, moduleTitle=Lancet oncol：派姆单抗联合西妥昔单抗治疗复发性/转移性HNSCC的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=122f21128838)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1629134, encodeId=9abe16291340c, content=<a href='/topic/show?id=f28e900536' target=_blank style='color:#2F92EE;'>#HNSCC#</a>, objectTitle=Radiother Oncol：西妥昔单抗-RT联合阿维单抗可用于治疗不适合顺铂治疗的晚期HNSCC患者, objectType=article, longId=198494, objectId=6962198494d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6962198494d6, replyNumber=0, likeNumber=65, createdTime=2020-08-02, rootId=0, userName=huirong, userId=27ec21318163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6962198494d6, moduleTitle=Radiother Oncol：西妥昔单抗-RT联合阿维单抗可用于治疗不适合顺铂治疗的晚期HNSCC患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6962198494d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1629133, encodeId=e8b816291332e, content=<a href='/topic/show?id=f28e900536' target=_blank style='color:#2F92EE;'>#HNSCC#</a>, objectTitle=Ann Oncol：抗PD-1/PD-L1治疗期间复发和/或转移性HNSCC患者的超表达, objectType=article, longId=108788, objectId=f369108e888d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f369108e888d, replyNumber=0, likeNumber=70, createdTime=2017-08-16, rootId=0, userName=huirong, userId=27ec21318163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f369108e888d, moduleTitle=Ann Oncol：抗PD-1/PD-L1治疗期间复发和/或转移性HNSCC患者的超表达, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f369108e888d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1629132, encodeId=fa8a1629132ff, content=<a href='/topic/show?id=f28e900536' target=_blank style='color:#2F92EE;'>#HNSCC#</a>, objectTitle=IJRO（Red）：EPO不能提高贫血HNSCC患者放化疗的局控率, objectType=article, longId=49055, objectId=0f9749055d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f9749055d7, replyNumber=0, likeNumber=71, createdTime=2015-04-09, rootId=0, userName=huirong, userId=27ec21318163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f9749055d7, moduleTitle=IJRO（Red）：EPO不能提高贫血HNSCC患者放化疗的局控率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f9749055d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HNSCC

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#DNA甲基化# #HNSCC# #头颈部鳞状细胞癌#

Cancer Res：南京医科大学程杰/王琰玲合作探索不同头颈部鳞状细胞癌亚型的生物特征和治疗易感性

2024-08-10发表于上海

huirong (审核中...)

前往app查看评论内容

#HNSCC#

Front Oncol：复发或转移性头颈部鳞癌(R/M HNSCC)患者使用免疫检查点抑制剂治疗(ICB)的疗效

2022-02-04

huirong (审核中...)

前往app查看评论内容

#HNSCC#

J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究

2022-01-23

huirong (审核中...)

前往app查看评论内容

#HNSCC#

Front Oncol：每周PCC方案（紫杉醇+卡铂+西妥昔单抗）可用于不适合EXTREME方案治疗复发和/或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者

2021-11-03

huirong (审核中...)

前往app查看评论内容

#HNSCC#

JNCCN：头颈部鳞状细胞癌(HNSCC)患者术后放疗（PORT）延迟会导致复发率增高并且OS降低

2021-09-26

zhaojie88 (审核中...)

前往app查看评论内容

#HNSCC#

Lancet oncol：派姆单抗联合西妥昔单抗治疗复发性/转移性HNSCC的疗效和安全性

2021-05-15

huirong (审核中...)

前往app查看评论内容

#HNSCC#

Radiother Oncol：西妥昔单抗-RT联合阿维单抗可用于治疗不适合顺铂治疗的晚期HNSCC患者

2020-08-02

huirong (审核中...)

前往app查看评论内容

#HNSCC#

Ann Oncol：抗PD-1/PD-L1治疗期间复发和/或转移性HNSCC患者的超表达

2017-08-16

huirong (审核中...)

前往app查看评论内容

#HNSCC#

IJRO（Red）：EPO不能提高贫血HNSCC患者放化疗的局控率

2015-04-09

科室
- - 订阅+
  - 更多科室
工具
服务